Terminated PHASE2 INTERVENTIONAL 2-arm NCT02318368

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label (FOCAL)

A Phase 2, Multicenter, Randomized, Double-blind Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label

Sponsor: AVEO Pharmaceuticals, Inc.

Conditions Non-small Cell Lung Cancer

Interventions Erlotinib Ficlatuzumab placebo

Updated 13 times since 2017 Last updated: Oct 20, 2020 Started: Nov 30, 2014 Primary completion: Jan 31, 2017 Completion: Jan 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor's decision

Other terminated trials from AVEO Pharmaceuticals, Inc.

More terminations from AVEO Pharmaceuticals, Inc.

Other Non-small Cell Lung Cancer trials with similar outcome

Browse all Non-small Cell Lung Cancer trials

A PHASE2 clinical study on Non-small Cell Lung Cancer, this trial is terminated or withdrawn. The trial is conducted by AVEO Pharmaceuticals, Inc. and has accumulated 13 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

13 versions recorded

Dec 2025 — Present [monthly]

Terminated PHASE2
Sep 2025 — Dec 2025 [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2

▶ Show 8 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Nov 2020 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE2
Jan 2018 — Jun 2018 [monthly]

Terminated PHASE2
Sep 2017 — Jan 2018 [monthly]

Terminated PHASE2
Jun 2017 — Sep 2017 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated
Feb 2017 — Jun 2017 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Nov 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AVEO Pharmaceuticals, Inc.
Biodesix, Inc.

Data source: AVEO Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bedford Park, Australia , Benevento, Italy , Boca Raton, United States , Bologna, Italy , Box Hill, Australia , Camperdown, Australia , Canton, United States , Central Singapore, Singapore , Chungcheongbuk-do, South Korea , Coffs Harbour, Australia and 32 more locations